KR102820082B1 - 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도 - Google Patents

항-her2/항-4-1bb 이중 특이 항체 및 이의 용도 Download PDF

Info

Publication number
KR102820082B1
KR102820082B1 KR1020227006642A KR20227006642A KR102820082B1 KR 102820082 B1 KR102820082 B1 KR 102820082B1 KR 1020227006642 A KR1020227006642 A KR 1020227006642A KR 20227006642 A KR20227006642 A KR 20227006642A KR 102820082 B1 KR102820082 B1 KR 102820082B1
Authority
KR
South Korea
Prior art keywords
ser
gly
val
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227006642A
Other languages
English (en)
Korean (ko)
Other versions
KR20220038768A (ko
Inventor
정혜진
용예령
박경수
박은영
정의정
이양순
김은정
손용규
손원준
안세원
염동훈
이찬무
홍정현
송무영
이은정
이나래
박영봉
김태왕
Original Assignee
주식회사유한양행
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사유한양행 filed Critical 주식회사유한양행
Priority to KR1020257019038A priority Critical patent/KR20250090381A/ko
Publication of KR20220038768A publication Critical patent/KR20220038768A/ko
Application granted granted Critical
Publication of KR102820082B1 publication Critical patent/KR102820082B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020227006642A 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도 Active KR102820082B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257019038A KR20250090381A (ko) 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962878951P 2019-07-26 2019-07-26
US62/878,951 2019-07-26
US202063024608P 2020-05-14 2020-05-14
US63/024,608 2020-05-14
PCT/KR2020/009871 WO2021020846A1 (en) 2019-07-26 2020-07-27 Anti-her2/anti-4-1bb bispecific antibody and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257019038A Division KR20250090381A (ko) 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도

Publications (2)

Publication Number Publication Date
KR20220038768A KR20220038768A (ko) 2022-03-29
KR102820082B1 true KR102820082B1 (ko) 2025-06-13

Family

ID=74190718

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227006642A Active KR102820082B1 (ko) 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도
KR1020257019038A Pending KR20250090381A (ko) 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257019038A Pending KR20250090381A (ko) 2019-07-26 2020-07-27 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도

Country Status (11)

Country Link
US (2) US12240913B2 (https=)
EP (1) EP4004054A4 (https=)
JP (2) JP7725446B2 (https=)
KR (2) KR102820082B1 (https=)
CN (2) CN118638240A (https=)
AU (1) AU2020320233A1 (https=)
BR (1) BR112022001336A8 (https=)
CA (1) CA3147423A1 (https=)
MX (1) MX2022001022A (https=)
WO (1) WO2021020846A1 (https=)
ZA (1) ZA202200906B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20211147A1 (es) 2019-08-12 2021-06-28 I Mab Biopharma Us Ltd Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso
CA3169910A1 (en) * 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Anti-cd137 constructs, multispecific antibody and uses thereof
KR20230042524A (ko) * 2020-08-07 2023-03-28 주식회사 유틸렉스 항-her2 / 항-4-1bb 이중특이적 항체 및 이의 용도
EP4281467A4 (en) * 2021-01-25 2024-12-04 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
MX2024005999A (es) * 2021-11-19 2024-05-30 Ap Biosciences Inc Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.
JP2025512915A (ja) * 2022-04-07 2025-04-22 ユハン コーポレーション Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物
KR20250148463A (ko) * 2024-04-03 2025-10-14 주식회사유한양행 담도암의 치료를 위한 항-her2/항-4-1bb 이중 특이 항체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156740A1 (en) * 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
US20190169308A1 (en) * 2016-04-22 2019-06-06 Alligator Bioscience Ab Novel bispecific polypeptides against cd137

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CA2984624A1 (en) 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
KR20170138574A (ko) 2015-05-04 2017-12-15 피어이스 파마슈티컬즈 게엠베하 항암 융합 폴리펩타이드
CN108064246A (zh) * 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
FI3436048T3 (fi) * 2016-03-31 2025-09-15 Biontech Us Inc Neoantigeeneja ja niiden käyttömenetelmiä
AU2017355544A1 (en) * 2016-11-03 2019-05-16 Juno Therapeutics, Inc. Combination therapy of a T cell therapy and a BTK inhibitor
SG11202000503QA (en) * 2017-07-20 2020-02-27 Aptevo Res & Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190169308A1 (en) * 2016-04-22 2019-06-06 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
WO2018156740A1 (en) * 2017-02-24 2018-08-30 Macrogenics, Inc. Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof

Also Published As

Publication number Publication date
EP4004054A4 (en) 2023-10-25
US20250163180A1 (en) 2025-05-22
US20210024650A1 (en) 2021-01-28
CN114206941B (zh) 2024-07-02
JP7725446B2 (ja) 2025-08-19
WO2021020846A1 (en) 2021-02-04
CN118638240A (zh) 2024-09-13
KR20220038768A (ko) 2022-03-29
MX2022001022A (es) 2022-04-18
BR112022001336A8 (pt) 2023-02-07
US12240913B2 (en) 2025-03-04
AU2020320233A1 (en) 2022-02-17
AU2020320233A8 (en) 2022-02-24
CA3147423A1 (en) 2021-02-04
JP2025179060A (ja) 2025-12-09
CN114206941A (zh) 2022-03-18
BR112022001336A2 (pt) 2022-03-22
ZA202200906B (en) 2023-11-29
JP2022542574A (ja) 2022-10-05
KR20250090381A (ko) 2025-06-19
EP4004054A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
KR102820082B1 (ko) 항-her2/항-4-1bb 이중 특이 항체 및 이의 용도
US20250066487A1 (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
TW202208438A (zh) 抗ｌｉｌｒｂ１抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞
CN115785268A (zh) 抗cd47抗体及其用途
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
RU2831838C2 (ru) Биспецифическое антитело анти-HER2/анти-4-1BB и его применение
RU2831836C2 (ru) Биспецифическое антитело анти-egfr/анти-4-1вв и его применение
HK40071708A (en) Anti-her2/anti-4-1bb bispecific antibody and use thereof
HK40072153A (en) Anti-egfr/anti-4-1bb bispecific antibody and use thereof
US20250215112A1 (en) Pharmaceutical composition for treating or preventing cancer with low expression level of her2
HK40071708B (zh) 抗her2/抗4-1bb双特异性抗体及其用途
US20240182593A1 (en) Ox40 agonist and use thereof
KR101926834B1 (ko) 항-dr5 항체 및 그의 용도
HK40072153B (zh) 抗egfr/抗4-1bb双特异性抗体及其用途
HK40113710A (zh) 用於治疗或预防her2低表达水平的癌症的药物组合物
HK40078173B (zh) 抗bcma/抗4-1bb双特异性抗体及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20220225

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20220919

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PA0302 Request for accelerated examination

Patent event date: 20240701

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241115

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250514

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250609

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration